Anika Therapeutics reported $20.97M in Gross Profit on Sales for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6055M 182M
Acorda Therapeutics ACOR:US $ 16.9M 10.42M
Adamas Pharmaceuticals ADMS:US 20.41M 725K
Agenus AGEN:US $ 10.61M 19.85M
Anika Therapeutics ANIK:US $ 20.97M 4.23M
Halozyme Therapeutics HALO:US $ 95.43M 35.68M
Immunogen IMGN:US $ 31793849155900M 31793849155900M
Insmed INSM:US $ 30.37M 183K
Integra Lifesciences IART:US $ 224.43M 29.21M
Johnson & Johnson JNJ:US $ 15285M 593M
Karyopharm Therapeutics KPTI:US $ 22.33M 11.72M
Ligand Pharmaceuticals LGND:US $ 47M 11.25M
Merit Medical Systems MMSI:US $ 111.89M 0.73M
Rigel Pharmaceuticals RIGL:US $ 80.7M 62.57M
Stryker SYK:US $ 2431M 342M
Surmodics SRDX:US $ 30.82M 12.27M
Veracyte VCYT:US $ 23.35M 2.6M